LINC01116 promotes proliferation, invasion and migration of osteosarcoma cells by silencing p53 and EZH2
- PMID: 31486480
- DOI: 10.26355/eurrev_201908_18720
LINC01116 promotes proliferation, invasion and migration of osteosarcoma cells by silencing p53 and EZH2
Abstract
Objective: The aim of this study was to elucidate the expression pattern and potential function of LINC01116 in regulating the progression of osteosarcoma.
Patients and methods: Expression levels of LINC01116 in osteosarcoma tissues (n=52) and adjacent normal tissues (n=52) were detected by quantitative Real-time polymerase chain reaction (qRT-PCR). Survival analysis and univariate analysis were performed in osteosarcoma patients based on the relative expression levels of LINC01116 and clinical data. Overexpression or silence of LINC01116 in osteosarcoma cells was achieved by transfection of plasmid complementary deoxyribonucleic acid (pcDNA)-LINC01116 or si-LINC01116, respectively. Subsequently, the regulatory effects of LINC01116 on cellular behaviors of osteosarcoma cells were examined by cell counting kit-8 (CCK-8), transwell and flow cytometry. Meanwhile, the potential mechanism of LINC01116 in regulating the progression of osteosarcoma was explored by RNA binding protein immunoprecipitation (RIP), chromatin immunoprecipitation (ChIP) and Western blot. Potential target genes in osteosarcoma were searched, and their functions were clarified through a series of rescue experiments.
Results: LINC01116 expression in osteosarcoma tissues was significantly higher than adjacent normal tissues. The expression of LINC01116 was negatively correlated with overall survival, whereas positively correlated with tumor size and clinical grade of osteosarcoma patients. Transfection of pcDNA-LINC01116 significantly enhanced proliferative, migratory and invasive abilities of U2OS cells, shortened G0/G1 phase period, and inhibited cell apoptosis. However, transfection of si-LINC01116 in MG63 cells obtained the opposite trends in the above-mentioned cellular behaviors. Furthermore, RIP assay confirmed the binding of enhancer of zeste homolog 2 (EZH2) to LINC01116. Knockdown of LINC01116 significantly up-regulated the expressions of phosphatase and tensin homolog deleted on chromosome ten (PTEN) and p53. Moreover, EZH2 knockdown could reverse the inhibitory effect of LINC01116 on carcinogenesis of osteosarcoma.
Conclusions: LINC01116 is highly expressed in osteosarcoma. Up-regulated LINC01116 can promote cell proliferation, invasion and cell cycle progression, while inhibiting the apoptosis of osteosarcoma cells. Furthermore, LINC01116 is involved in the development of osteosarcoma by binding to EZH2 to regulate expressions of PTEN and p53.
Similar articles
-
LncRNA LINC00673 inhibits p53 expression by interacting with EZH2 and DNMT1 in papillary thyroid carcinoma.Eur Rev Med Pharmacol Sci. 2019 Mar;23(5):2075-2083. doi: 10.26355/eurrev_201903_17249. Eur Rev Med Pharmacol Sci. 2019. PMID: 30915752
-
LINC01116 facilitates colorectal cancer cell proliferation and angiogenesis through targeting EZH2-regulated TPM1.J Transl Med. 2021 Jan 26;19(1):45. doi: 10.1186/s12967-021-02707-7. J Transl Med. 2021. PMID: 33499872 Free PMC article.
-
Knockdown of ZEB2-AS1 inhibits cell proliferation, invasion and induces apoptosis in osteosarcoma by combining with EZH2.Eur Rev Med Pharmacol Sci. 2020 Jun;24(12):6533-6539. doi: 10.26355/eurrev_202006_21637. Eur Rev Med Pharmacol Sci. 2020. PMID: 32633340
-
FOXP4-AS1 participates in the development and progression of osteosarcoma by downregulating LATS1 via binding to LSD1 and EZH2.Biochem Biophys Res Commun. 2018 Aug 25;502(4):493-500. doi: 10.1016/j.bbrc.2018.05.198. Epub 2018 Jun 5. Biochem Biophys Res Commun. 2018. PMID: 29859193
-
Promising Advances in LINC01116 Related to Cancer.Front Cell Dev Biol. 2021 Oct 14;9:736927. doi: 10.3389/fcell.2021.736927. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34722518 Free PMC article. Review.
Cited by
-
LncRNAs could play a vital role in osteosarcoma treatment: Inhibiting osteosarcoma progression and improving chemotherapy resistance.Front Genet. 2023 Jan 16;13:1022155. doi: 10.3389/fgene.2022.1022155. eCollection 2022. Front Genet. 2023. PMID: 36726721 Free PMC article. Review.
-
LncRNA LINC01116 Contributes to Cisplatin Resistance in Lung Adenocarcinoma.Onco Targets Ther. 2020 Sep 22;13:9333-9348. doi: 10.2147/OTT.S244879. eCollection 2020. Onco Targets Ther. 2020. Retraction in: Onco Targets Ther. 2023 Jul 19;16:615-616. doi: 10.2147/OTT.S430432 PMID: 33061421 Free PMC article. Retracted.
-
HOXDeRNA activates a cancerous transcription program and super enhancers via genome-wide binding.Mol Cell. 2024 Oct 17;84(20):3950-3966.e6. doi: 10.1016/j.molcel.2024.09.018. Epub 2024 Oct 8. Mol Cell. 2024. PMID: 39383879
-
Knocking down LINC01116 can inhibit the regulation of TGF-β through miR-774-5p axis and inhibit the occurrence and development of glioma.Am J Transl Res. 2021 May 15;13(5):5702-5719. eCollection 2021. Am J Transl Res. 2021. PMID: 34150180 Free PMC article.
-
Anticancer effects of melatonin via regulating lncRNA JPX-Wnt/β-catenin signalling pathway in human osteosarcoma cells.J Cell Mol Med. 2021 Oct;25(20):9543-9556. doi: 10.1111/jcmm.16894. Epub 2021 Sep 21. J Cell Mol Med. 2021. PMID: 34547170 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous